Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Wednesday, 31 January 2018

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

FIT Biotech Oy    

Published: 14:30 CET 31-01-2018 /GlobeNewswire /Source: FIT Biotech Oy / : FITBIO /ISIN: FI4000148606

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

FIT Biotech Oy

Company release January 31, 2018 at 3.30 pm EET

 

 

FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

 

FIT Biotech Oy's Board of Directors has resolved to issue 100,000,000 new K shares without payment to the Company itself based on the authorization granted by the extraordinary general meeting on December 14, 2017 (Extraordinary general meeting Point 9§).

 

The total authorization was 550,000,000 K shares. The Board of Directors has decided earlier on December 27, 2017 to issue 80,000,000 new K shares. There are authorizations for 370,000,000 K shares left after this issuance.

 

The purpose is partly to use the shares to implement the new Alpha Blue Ocean funding programme, disclosed on December 23, 2017 and partly to implement the remaining part of the Bracknor funding programme.

 

FIT BIOTECH OY

Board of Directors

 

 

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
E-mail: erkki.pekkarinen@fitbiotech.com

 

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

 

 

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

 

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

 

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

 

 

DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: FIT Biotech Oy, Biokatu 8, Tampere FI-33520, Finland
If you would like to unsubscribe and stop receiving these e-mails click here.